Abstract: SA-PO0791
Pegcetacoplan Subcutaneous Infusion: Early Access and Patient Training
Session Information
- Glomerular Research: Design, Registries, Surveys, and Epidemiology
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Akutek, Martin, Penn Medicine, Philadelphia, Pennsylvania, United States
- Coppock, Gaia M., Penn Medicine, Philadelphia, Pennsylvania, United States
- Bleicher, Melissa, Penn Medicine, Philadelphia, Pennsylvania, United States
- Holzman, Lawrence B., Penn Medicine, Philadelphia, Pennsylvania, United States
- Shulman, Rachel, Penn Medicine, Philadelphia, Pennsylvania, United States
- Geara, Abdallah Sassine, Penn Medicine, Philadelphia, Pennsylvania, United States
Background
Alternative complement cascade dysregulation is the main pathogenesis for C3 Glomerulopathy (C3G) and idiopathic immune complex membranoproliferative glomerulonephritis (IC-MPGN). Both diseases are progressive, with a 30-50% risk of kidney failure within 10 years and high risk for recurrence after kidney transplant. Often treated with corticosteroid and mycophenolate with variable success, oral complement inhibitor, iptacopan, has been approved for C3G therapy. Pegcetacoplan showed positive results for both C3G and IC-MPGN in pre- and post-transplant patients. It binds to complement protein C3 and C3b, thereby regulating the cleavage of C3 and the generation of downstream effectors of complement. Pegcetacoplan is a self-administered subcutaneous infusion (SCI), eliminating the need for infusion center visits.
Methods
Pegcetacoplan SCI 1080 mg twice weekly was given to 8 patients with C3G and IC-MPGN via the Freedom Edge syringe infusion system with an infusion time of 30-60 minutes. Patients or caregivers were trained by a nurse either inperson or remotely. Patient demographics are detailed in the table. The cohort was equally split between male and female, IC-MPGN and C3G, pre- and post-transplant.
Results
All participants received 1 in-person training session except one who received 2 in-person sessions, one patient had one remote session. Our cohort accumulated a total of 67 months with twice weekly SCI of pegcetacoplan. Only one patient discontinued the therapy after two months due to a lack of benefit. There were no reported difficulties or adverse events related to the SCI administration or adverse effects with pegcetacoplan
Conclusion
Patients can safely self-administered SCI infusions of pegcetacoplan with minimal training. One in-person training session was sufficient to make patients competent in self-administration and remote training was also successfully used.
| Patient | Age | Sex | Race | Education | Diagnosis | Post-Transplant | Training | Duration of Therapy |
| 1 | 26 | M | White | College | IC-MPGN | Yes | One session Inperson | 10 months |
| 2 | 45 | M | Hispanic | High School | IC-MPGN | No | One session Inperson | 9 months |
| 3 | 35 | M | White | College | C3G | Yes | One session Inperson | 24 months |
| 4 | 65 | F | White | College | C3G | Yes | One session Inperson | 7 months |
| 5 | 56 | F | White | College | IC-MPGN | No | One session Inperson | 7 months |
| 6 | 21 | M | White | College | C3G | No | One session Remote | 5 months |
| 7 | 62 | F | IC-MPGN | College | IC-MPGN | No | Two sessions Inperson | 2 months |
| 8 | 21 | F | White | High School | C3G | Yes | One session Inperson | 3 months |